CD37 and primary cutaneous T-cell non-Hodgkin lymphoma: The CD37 CAR-T cells developed by Scarfo’s team for CTCL were shown to specifically activate and secrete cytokines to effectively kill CTCL cell lines from patients (e.g., HuT78) in in vitro experiments with no apparent T-cell self-interaction [40].